Evidence map›Paper›PMID 29057301›Full record

ArticleMolecular & cellular oncology2017

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer.

C Gamell, T Gulati, B Solomon, S Haupt, Y Haupt

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

C GamellThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
T GulatiThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
B SolomonThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
S HauptThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Y HauptThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
University of Melbourne · AUPeter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16

Indexed as

CDC6E6APINK4/ARFNSCLCp16tumor suppression

Identifiers

PMID29057301
PMCPMC5644485
OpenAlexW2591962377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.